Recent Updates
Recently added Catalysts

diclofenac

Phase 3

Acute Ankle Sprain | Small molecule | Musculoskeletal |Novartis AG|Last Updated: Dec 21, 2020

Target and mechanism

ModalitySmall molecule

Also known as Diclofenac Topical Sodium Gel 1%, Diclofenac 1%, Diclofenac sodium topical gel 1%, Diclofenac sodium gel 1%, Diclofenac potassium, Diclofenac topical sodium gel 1%, Diclofenac Sodium Gel, Diclofenac Sodium

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment205

FDA Designations

No designations recorded

Clinical trial landscape

diclofenac · 14 trials · 11 indications

Phase 3 12Phase 1 2
NCT02476422A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental PainPost Operative Dental Pain
COMPLETED328 Analytics
NCT02271854A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle SorenessMuscle Soreness
COMPLETED102 Analytics
NCT01272934Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Ankle SprainAcute Ankle Sprain
COMPLETED205 Analytics
NCT01272947Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Blunt Trauma InjuriesAcute Blunt Soft Tissue Injuries/Contusions
COMPLETED204 Analytics
NCT01255423Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle SprainAnkle Sprain
COMPLETED206 Analytics
NCT00426621Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee OsteoarthritisOsteoarthritis of the Knee
COMPLETED420 Analytics
NCT00441051Efficacy and Safety of Diclofenac Sodium (0.1%) Gel in Patients With UV Induced Painful SunburnSunburn
COMPLETED45 Analytics
NCT00171652Efficacy and Safety of Diclofenac Sodium Gel in Hand OsteoarthritisOsteoarthritis
COMPLETED360 Analytics
NCT00171665Efficacy and Safety of Diclofenac Sodium Gel in Hand OsteoarthritisOsteoarthritis
COMPLETED360 Analytics
NCT00171678Efficacy and Safety of Diclofenac Sodium Gel in Knee OsteoarthritisOsteearthritis
COMPLETED480 Analytics
PHASE3COMPLETED
A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain
Post Operative Dental PainUnlock trial analytics
PHASE3COMPLETED
A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness
Muscle SorenessUnlock trial analytics
PHASE3COMPLETED
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Ankle Sprain
Acute Ankle SprainUnlock trial analytics
PHASE3COMPLETED
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Blunt Trauma Injuries
Acute Blunt Soft Tissue Injuries/ContusionsUnlock trial analytics
PHASE3COMPLETED
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain
Ankle SprainUnlock trial analytics
PHASE3COMPLETED
Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis
Osteoarthritis of the KneeUnlock trial analytics
PHASE3COMPLETED
Efficacy and Safety of Diclofenac Sodium (0.1%) Gel in Patients With UV Induced Painful Sunburn
SunburnUnlock trial analytics
PHASE3COMPLETED
Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis
OsteoarthritisUnlock trial analytics
PHASE3COMPLETED
Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis
OsteoarthritisUnlock trial analytics
PHASE3COMPLETED
Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
OsteearthritisUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline in Visual Analog Scale of Pain Intensity (VASPI) at 60 Minutes Post Dose
60 minutes postdose

VASPI reduction from baseline is the difference between the Baseline VASPI score and the VASPI score at a specific observation point. Subjects were asked to identify their current level of pain intensity on the 100 mm VASPI, labeled "no pain" (0 mm) as the left anchor and "worst possible pain" (100 mm) as the right anchor. A positive change represents a reduction in pain.

Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW.
24 hours

The primary efficacy outcome was the time-weighted SPID 24 (POW). Sum of pain intensity differences over 24 hours after initiating treatment (SPID 24) for the modified ITT population. SPID 24 derived from Pain on Walking (POW) scores assessed over 24 hours on a 0 (No pain) - 10 (Pain as bad as you can imagine) Numerical Rating Scale. SPID 24 was computed using the trapezoidal rule, i.e. Σ \[T(i) - T(i-1)\] x \[((PID)(i-1) + PID(i))/2\] in an obvious notation, where T(i) is nominal time and PID(i), the pain intensity difference at Time i, is the baseline pain intensity (PI) score - PI score at Time i.

Pain on Movement
72 hours

Pain on Movement at 72 hours assessed on a 100 mm visual analog scale with anchors at 0="No pain" and 100= "Extreme pain"

pain in the target knee (WOMAC pain index);
functional capacity in the target knee (WOMAC function index); and
global rating of benefit (100 mm Visual Analogue Scale, VAS).
Assess by Visual Analogue Scale (VAS)how products relieve provoked pain (by gloved finger)associated with sunburn in the first 24 hours after UV irradiation.
OA pain intensity in target hand at Week 4 and 6
Total AUSCAN score in target hand at Week 4 and 6
Global rating of disease activity by patient at Week 4 and 6
WOMAC pain score in target knee at Week 12
WOMAC physical function score in target knee at Week 12
Global rating of disease activity by patient at Week 12
Incidence of treatment-emergent adverse events
Number of laboratory values outside pre-determined ranges at Months 1, 3, 6, 9 and 12
Probe substrate pharmacokinetics (PK) parameters: Cmax (Maximum (peak) concentration of drug)
multiple time-points over 24h post dose on day 1 and Day 13 (DDI phase),
Probe substrate PK parameters: AUCtlast (Area Under the Curve)
multiple time-points over 24h post dose on day 1 and Day 13 (DDI phase),
Probe substrate PK parameters: AUCinf
multiple time-points over 24h post dose on day 1 and Day 13 (DDI phase),
Probe substrate PK parameters:Tmax (Time to maximum concentration)
multiple time-points over 24h post dose on day 1 and Day 13 (DDI phase),
Probe substrate PK parameters: HL (Half-life time)
multiple time-points over 24h post dose on day 1 and Day 13 (DDI phase),
Probe substrate PK parameters:CL/F (Apparent Oral Clearance)
multiple time-points over 24h post dose on day 1 and Day 13 (DDI phase),
Probe substrate PK parameters:Vz/F (apparent volume of distribution)
multiple time-points over 24h post dose on day 1 and Day 13 (DDI phase),
Bioequivalence based on AUC and Cmax
17 days

Secondary Endpoints

Change From Baseline in Visual Analog Scale of Pain Intensity (VASPI) at Different Time Points
15, 30, 45, and 90 minutes, and 2, 4, 5, 6, 7, and 8 hours post dose
Area Under the Curve (AUC) of Visual Analog Scale of Pain Intensity (VASPI) Measuring Change From Baseline at Different Time Points
15, 30, 45, 60 and 90 minutes, and 2, 4, 5, 6, 7, and 8 hours post dose
Time to Confirmed First Perceptible Pain Relief
Within 8 hours postdose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Dilcofenac potassium + placebo to IbuprofenEXPERIMENTALSingle dose of diclofenac potassium 50 mg soft gelatin capsule was given once patient developed moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to ibuprofen 400 mg tablet was also given to patient in order to maintain double dummy method.
Ibuprofen + placebo to diclofenac potassiumACTIVE_COMPARATORSingle dose of ibuprofen 400 mg tablet was given once patient develops moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule was also given to patient in order to maintain double dummy method.
diclofenac sodium gel 1%EXPERIMENTALdiclofenac sodium gel 1% applied four times daily
PlaceboPLACEBO_COMPARATORPlacebo gel applied four times daily
Diclofenac sodium topical gel 1%EXPERIMENTALDiclofenac sodium topical gel 1%
1EXPERIMENTAL -
2PLACEBO_COMPARATOR -
TKI258 (dovitinib)EXPERIMENTALdovitinib, 5 days on / 2 days off dose schedule

Interventions

NameTypeDescription
Diclofenac potassiumDRUGSingle dose of diclofenac 50 mg soft gelatin capsule
IbuprofenDRUGSingle dose of ibuprofen 400 mg tablet
Placebo to ibuprofenDRUGSingle dose of placebo to ibuprofen 400 mg tablet
Placebo to diclofenac potassiumDRUGSingle dose of placebo to diclofenac potassium 50 mg soft gelatin capsule
Diclofenac sodium gel 1%DRUGDiclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
PlaceboDRUGPlacebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
Diclofenac SodiumDRUGTopical gel 1%-4 times daily
Diclofenac sodium topical gel 1%DRUGDiclofenac sodium topical gel 1%, 4 times daily
Diclofenac Sodium GelDRUG4 grams per knee, 4 times per day, for 12 weeks
Diclofenac sodium 1mg/gDRUG -
Diclofenac topical sodium gel 1%DRUG -
caffeineDRUGsingle dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
diclofenacDRUGsingle dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
omeprazoleDRUGsingle dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
midazolamDRUGsingle dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
TKI258DRUGdovitinib, 5 days on / 2 days off dose schedule
Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)DRUG -
Voltaren 50 mg Tablets (Geigy Pharmaceuticals)DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites1

Key Inclusion Criteria: * Patients requiring surgical removal of 2 ipsilateral third molars, of which the mandibular must be fully or partially impacted. The ipsilateral maxillary third molar may be of any impaction level. * Patients having a moderate to severe Baseline pain intensity as assessed b...

Countries:United StatesGermanyFrance
Unlock Eligibility Criteria